Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 4Phase 1/2 4Phase 3 1

Status

Completed 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 7Multiple Myeloma 4Lymphoma, T-Cell 4Lymphoma, Non-Hodgkin 4Waldenstrom Macroglobulinemia 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Burkitt Lymphoma 3Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Oligodendroglioma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Immunoblastic 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms, Male 1

Interventions

Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 5romidepsin 4pembrolizumab 4Lenalidomide 4Etoposide 410-propargyl-10-deazaaminopterin 4Rituximab 3fludarabine phosphate 2fludarabine 2durvalumab 2carmustine, poliferprosan 20 drug combination 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Melphalan 2Gemcitabine 2Doxorubicin 2Depsipeptides 2Cytarabine 2Carmustine 2Bendamustine Hydrochloride 2AFM13 2veliparib 1thymoglobulin 1tenalisib 1temsirolimus 1prednylidene 1mogamulizumab 1forodesine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell × romidepsin × Clear all
NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
39 enrolled
DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT02341014 2024-04-04

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
27 enrolled 13 charts
Lymphoid

Lymphoma, Recurrence, Lymphoma, T-Cell

NCT03770000 2022-10-28

Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma

Rhizen Pharmaceuticals SA

Phase 1/2 Completed
33 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell

NCT03161223 2022-03-31

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

University of Virginia

Phase 1/2 Recruiting
148 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡